UBS Group AG Decreases Stock Position in KalVista Pharmaceuticals, Inc. $KALV

UBS Group AG lessened its stake in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 18.1% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 371,993 shares of the specialty pharmaceutical company’s stock after selling 82,155 shares during the period. UBS Group AG’s holdings in KalVista Pharmaceuticals were worth $6,008,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Tudor Investment Corp ET AL purchased a new stake in KalVista Pharmaceuticals in the third quarter worth $24,360,000. Emerald Advisers LLC increased its stake in KalVista Pharmaceuticals by 30.2% in the third quarter. Emerald Advisers LLC now owns 1,351,254 shares of the specialty pharmaceutical company’s stock worth $16,458,000 after purchasing an additional 313,205 shares during the period. Jefferies Financial Group Inc. purchased a new stake in KalVista Pharmaceuticals in the third quarter worth $3,494,000. Blue Owl Capital Holdings LP purchased a new stake in KalVista Pharmaceuticals in the third quarter worth $1,522,000. Finally, Emerald Mutual Fund Advisers Trust increased its stake in KalVista Pharmaceuticals by 19.4% in the third quarter. Emerald Mutual Fund Advisers Trust now owns 917,975 shares of the specialty pharmaceutical company’s stock worth $11,181,000 after purchasing an additional 149,003 shares during the period.

Insider Buying and Selling at KalVista Pharmaceuticals

In other news, CFO Brian Piekos sold 1,862 shares of the stock in a transaction on Friday, April 17th. The stock was sold at an average price of $20.22, for a total transaction of $37,649.64. Following the transaction, the chief financial officer owned 18,150 shares of the company’s stock, valued at approximately $366,993. This represents a 9.30% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, major shareholder Venrock Healthcare Capital Par sold 174,645 shares of the stock in a transaction on Wednesday, March 25th. The stock was sold at an average price of $16.95, for a total value of $2,960,232.75. Following the transaction, the insider directly owned 5,129,340 shares in the company, valued at $86,942,313. The trade was a 3.29% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 261,736 shares of company stock worth $4,539,236. Insiders own 4.30% of the company’s stock.

KalVista Pharmaceuticals Price Performance

KALV opened at $26.81 on Thursday. KalVista Pharmaceuticals, Inc. has a 12-month low of $9.83 and a 12-month high of $26.85. The company has a current ratio of 5.17, a quick ratio of 5.10 and a debt-to-equity ratio of 8.18. The business’s fifty day simple moving average is $21.02 and its 200-day simple moving average is $17.09. The company has a market capitalization of $1.43 billion, a price-to-earnings ratio of -7.75 and a beta of -0.12.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its quarterly earnings results on Friday, May 15th. The specialty pharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). The firm had revenue of $39.17 million during the quarter, compared to analyst estimates of $39.03 million. On average, equities research analysts anticipate that KalVista Pharmaceuticals, Inc. will post -0.96 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research note on Tuesday, April 21st. Leerink Partners lowered KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 29th. Citizens Jmp lowered KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 29th. Wall Street Zen lowered KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, April 21st. Finally, Needham & Company LLC lowered KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, April 30th. Three equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, KalVista Pharmaceuticals has an average rating of “Hold” and a consensus target price of $30.60.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.